Truvada Gets FDA Nod for HIV Prevention

Other experts in the field agreed with this assessment.

"The approval of Truvada to prevent HIV infection in uninfected individuals who are at high risk of sexually acquired HIV infection is a significant development, providing an important addition to our toolkit of HIV prevention interventions," said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Disease. "However, it is critical to stress that Truvada as 'pre-exposure prophylaxis' should not be considered a stand-alone method, but should be used in conjunction with other proven HIV prevention strategies."

Not everyone was in favor of the approval. The AIDS Healthcare Foundation, a global organization involved in providing treatment to AIDS/HIV patients, strongly criticized the move, calling it irresponsible and saying Truvada's approval for this use would undermine current prevention efforts.

AHF president Michael Weinstein questioned whether the fact that support provided to study participants -- such as monthly HIV testing and intensive counseling -- would not be available to the general population would lead to decreased adherence to the drug regimen, and thus to the development of drug-resistant strains. Weinstein further cautioned that the drug's side effects on the kidneys and bones might be worth accepting in patients who needed to be treated for HIV, but were not worth the risk on otherwise healthy individuals.

"Today marks a catastrophe in the history of AIDS in America," he said.

While the AHF criticized the approval, a number of experts said there are many high risk individuals who won't use condoms but might take a daily pill.

"It's argued that PrEP is far more expensive than condoms, but it's a lot cheaper than a lifetime of HIV treatment," said Dr. Joel Gallant of the Johns Hopkins Center for Global Health. "If we can target PrEP to those at highest risk, PrEP is likely to be cost-effective."

More from ABC News HIV Prevention Pill Strengthens BondCritics Pan HIV Prevention PillMajor Breakthrough in HIV PreventionHIV Prevention Setback: Drug Trial HaltedAntiretroviral Drugs May Prevent HIV InfectionAIDS Prevention Pill Ineffective for Women More Video » Related Topics: HIV, Infectious Diseases, Sexually Transmitted Diseases, Food And Drug Administration, Gilead Sciences, Contraception, Side Effects, U.S., Allergy, Kidney Health Follow

View the Original article

FDA Approves Truvada as First HIV Prevention Drug

in addition, patients must also practice safe sex, go through risk reduction counseling and undergo regular HIV testing.

Because of the stringent guidelines the FDA is strengthening the box warnings that patients must be confirmed that they’re HIV negative and must be tested for the virus every three months while they’re on the medication.

View the Original article

FDA staff: Gilead's Truvada may help reduce HIV risk

'modId':'mediatabs_nmid_1_conv_prom','isPreLoad':0,'enableMediaTabEvent':0,'pageSize':12,'numFriends':null,'notificationCount':0,'property':'News','learnMorePath':'/activity-learn-more/','friendbarNotification':'0','friendbarRollup':'0','moduleConf':YAHOO.Media.Facebook.ModuleConf,'friendIdList':

View the Original article